| Literature DB >> 26285460 |
J Y Reginster, A Neuprez, M P Lecart, C Beaudart, F Buckinx, J Slomian, O Bruyère.
Abstract
Osteoporosis is at the very early stages of the implementation of personalized medicine. However, the development of FRAX®, an algorithm offering the opportunity to calculate, in an individual patient, his/her 10-year fracture risk improves the decision process on the appropriateness to initiate a pharmacological treatment. This algorithm helps the physician to select drugs which are active on non-vertebral fractures only in high risk patients. Taking into consideration patients' preferences, when selecting a therapeutic option, will improve long term adherence and subsequently efficacy and efficiency of the treatments. Attempts to define the natural course of osteoporosis or the response to therapy in individual patients by assessing their genetic profile remains, so far, inconclusive.Entities:
Mesh:
Year: 2015 PMID: 26285460
Source DB: PubMed Journal: Rev Med Liege ISSN: 0370-629X